Atrial Fibrillation After Ischemic Stroke Detected by Chest Strap-Style 7-Day Holter Monitoring and the Risk Predictors: EDUCATE-ESUS

Yuichi Miyazaki1, 2, Kazunori Toyoda3, Yasuyuki Iguchi3, Teruyuki Hirano4, Norifumi Metoki5, Masanori Tomoda2, Masayuki Shiozawa1, Junpei Koge1, Yasushi Okada2, Yuka Terasawa3, Muneaki Kikuno1, Haruko Okano4, Joji Hagii3, Masanori Nakajima4, Teppi Komatsu3 and Masahiro Yasaka2

1 Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan
2 Department of Cerebrovascular Medicine and Neurology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
3 Department of Neurology, the Jikei University School of Medicine, Tokyo Japan
4 Stroke Center, Kyorin University Hospital, Tokyo Japan
5 Department of Internal Medicine, Hirosaki Stroke and Rehabilitation Center, Hirosaki, Japan

Aim: This study aimed to investigate the diagnostic yield of 7-day Holter monitoring for detecting covert atrial fibrillation (AF) in patients with recent embolic stroke of undetermined source (ESUS) and to identify the pre-entry screening biomarkers that had significant associations with later detection of AF (clinicaltrials.gov. NCT02801708).

Methods: A total of 206 patients who have recent ESUS without previously documented AF underwent Holter electrocardiography using a chest strap-style monitor. External validation of biomarkers predictive of AF was performed using 83 patients with ESUS who were implanted with insertable cardiac monitors.

Results: The 7-day Holter monitoring started at a median of 13 days after the onset of stroke. AF was detected in 14 patients, and three of these showed a single AF episode lasting ʻ2 min. The median time delay to the first documented AF was 50 h. Each of serum brain natriuretic peptide ≥ 66.0 pg/mL (adjusted odds ratio 5.23), atrial premature contractions (APCs) ≥ 345 beats (3.80), and APC short runs ≥ 13 (5.74) on 24-h Holter prior to the 7-day Holter showed a significant association with detection of AF, independent of age and physiological findings in this derivation cohort, and all of these showed a significant association in the validation cohort (adjusted odds ratio 6.59, 7.87, and 6.16, respectively).

Conclusions: In recent ESUS patients, the detection rate of AF using the 7-day Holter monitoring was 6.8% (95% CI 4.1%–11.1%). Brain natriuretic peptide, APC count, and APC short runs in the standard clinical workup seemed to be predictors of covert AF.

Key words: Acute stroke, Atrial premature contraction, Brain natriuretic peptide, Cardioembolism, Insertable cardiac monitors

Introduction

Recent advances in diagnostic techniques have shown that most “cryptogenic strokes,” i.e., ischemic stroke of uncertain cause, are embolic1-3). Thus, the term “embolic stroke of undetermined source (ESUS)” has been proposed as a new clinical entity to refine its definition. Covert atrial fibrillation (AF) is thought to be relatively common among potential embolic sources of ESUS.
AF is a leading cause of cardioembolic stroke\(^4\). The efficacy of anticoagulant therapy, including vitamin K antagonists and direct oral anticoagulants (DOACs), has been established in stroke prevention for patients with non-valvular AF\(^5\). Thus, the same therapeutic regimen would also be efficacious for ESUS patients\(^1\). However, two randomized controlled trials failed to demonstrate that DOACs were superior to aspirin for the secondary prevention of ESUS\(^8\). Oral anticoagulants cannot be recommended on the basis of current evidence; therefore, detecting covert AF has important therapeutic implications in patients with ESUS.

However, being often paroxysmal and asymptomatic, AF can be missed with the conventional workup after stroke, such as electrocardiography (ECG) monitoring for 24 h, which was recommended in the current guidelines\(^1\). Randomized controlled trials have proven that cardiac monitoring that last longer than 24 h clearly increases the probability of AF detection after ischemic stroke or transient ischemic attack\(^12,14\), with the best results obtained by 3-year insertable cardiac monitoring devices\(^15\). However, considering their noninvasiveness and low cost, wearable devices for several-day monitoring would also be useful in practical clinical settings\(^15\).

### Aim

This present study aimed to investigate the diagnostic yield of a recently developed chest strap-style, ambulatory, 7-day Holter monitor for detecting covert AF in patients with recent ESUS and to determine the pre-entry screening biomarkers with significant associations with later detection of AF.

### Methods

The enhanced detection of underlying covert atrial fibrillation using 7-day Holter electrocardiogram in patients with embolic stroke of undetermined source (EDUCATE-ESUS) was a multicenter (five stroke centers), prospective observational study. The prespecified inclusion criteria were patients aged ≥ 20 years without previously documented AF who were admitted within 3 months from stroke onset and who were diagnosed with ESUS. ESUS was defined using the following criteria, which were essentially identical with those of the Cryptogenic Stroke/ESUS International Working Group:\(^1\) (1) ischemic stroke or transient ischemic attack with positive neuroimaging that is not lacunar, (2) absence of ≥ 50% stenosis or occlusion in cervical and intracranial arteries supplying the ischemic area, (3) no documentation of AF on 24-h Holter ECG, (4) no intracardiac thrombi on transthoracic echocardiography, (5) no other major cardioembolic sources, and (6) no other specific cause of stroke (e.g., arteritis, dissection, and vasospasm). The study was approved by each institutional review board (M29-030 in the National Cerebral and Cardiovascular Center), and informed consent was collected from all patients. The study was registered with the ClinicalTrials.gov identifier NCT02801708.

All patients underwent 7-day Holter ECG monitoring using the EV-201 (Parama-Tech, Fukuoka, Japan), a chest strap-style monitor that is capable of 168 h of continuous single-lead ECG recording on a micro secure digital card (Fig. 1). Patients could easily attach the recorder by themselves, could remove them before bathing or showering, and could then attach it again later with ease. Monitoring was performed within 3 months of stroke onset. The ECG recordings were analyzed by specially trained persons and were reviewed by another cardiac electrophysiology specialist. AF was defined as an ECG showing absolutely irregular R–R intervals without detectable P waves. If AF was detected, the details of the AF episodes were analyzed, including their duration, burden (defined as the proportion of time when AF episodes were recorded during a monitoring period), and time from the start of the examination to the first AF.

Baseline characteristics, including patient demographics, medical history, physiological data on admission, and stroke characteristics, were reviewed. In
addition, blood testing was done on admission, and transthoracic echocardiography and 24-h Holter monitoring were performed early in the hospitalization. Variables obtained from these three examinations were used to determine the predictors for detection of AF with the 7-day Holter monitoring. All data were recorded online with electronic data capture system.

The outcome measures were detection of AF of any duration using the 7-day Holter monitor, duration of the longest AF episode, AF burden, the time from the start of the monitoring to the first AF detection.

External validation of biomarkers predictive of AF was performed using an ongoing prospective single-center database (the National Cerebral and Cardiovascular Center Stroke Registry, ClinicalTrials.gov Identifier: NCT02251665). Consecutive patients who were admitted after the onset of acute ESUS and who started monitoring with insertable cardiac monitors (Reveal LINQ, Medtronic, Minneapolis, MN) were studied. Indications for the monitors were judged based on unique diagnostic criteria for ESUS, in accordance with current medical practice in Japan, such as mandatory screening with brain magnetic resonance imaging.

Statistical Analysis

Data are presented as median [interquartile range (IQR)] or numbers (%). Baseline characteristics and the 7-day Holter findings were compared between patients with AF and those without. Continuous variables were compared using the Wilcoxon rank-sum test. Comparisons of categorical variables were performed using the chi-squared test or Fisher’s exact test, as applicable. Multivariate logistic regression analysis was performed to identify pre-entry screening biomarkers associated with detection of AF using the variables showing \( P < 0.05 \) on univariate analysis. A receiver operating characteristic (ROC) curve analysis was performed to determine the optimal cutoff level of each biomarker. Statistical analysis was performed using Stata/SE 15.1 (StataCorp, College Station, TX, USA) with two-tailed \( p \) values \( < 0.05 \) considered significant.

Results

A total of 206 patients (median age 71 years, 75 women) were enrolled in the present study between September 2014 and December 2017. Table 1 presents the baseline clinical characteristics of the study population.

Detection of Atrial Fibrillation using the 7-Day Holter Monitoring

The 7-day Holter monitoring started at a median of 13 days (IQR 9–19 days) after stroke onset in the inpatient setting for 121 patients (59%) and in the outpatient setting for the remaining 85 patients. The median time of total ECG recording was 168.3 h (IQR 167.0–172.4 h), and the time did not reach 100 h in 11 patients (5%, 40.6–98.0 h). No technical problems were encountered by the patients in handling the device themselves. Any non-mild adverse events related to the examination were documented. The only mild adverse event was a transient skin rash related to wearing the device in 16 patients (8%).

AF with any duration was detected in 14 patients [6.8%, 95% confidence interval (CI) 4.1%–11.1%]. The median longest duration of AF was 50 min (IQR 25–236 min, Fig. 2A). It lasted >30 min in 11 patients (#1–13) and 67, 46, and 15 s in the remaining 3 patients (#12–14, respectively). Thirteen patients (6.3%, except for #14) met the definition of paroxysmal AF in the current guidelines (≥ 30 s)\(^{10}\). The median AF burden during the monitoring period amounted to 4.9% (IQR 0.9%–10.6%, Fig. 2B). AF was detected only once in the three patients with the longest duration of AF < 2 min (#12–14). The median interval between the start of monitoring and the first documentation of AF was 50 h (IQR 25–236 h, Fig. 2C). The median interval between stroke onset and the initiation of monitoring was 10.5 days for these 14 patients versus 13 days for the remaining patients without documentation of AF (\( P = 0.69, \) Table 1). The detection rates of AF during the quartile periods between stroke onset and the start of monitoring were 8.2% (4/49) in the first quartile (≤ 8 days), 7.0% (4/53) in the second (9–13 days), 2.1% (1/47) in the third (14–18 days), and 9.6% (5/47) in the fourth (≥ 19 days, \( P = 0.39 \)).

Association of Baseline Characteristics with Detection of Atrial Fibrillation

Patients with AF identified on the 7-day Holter monitoring were found to be older than the remaining patients without documentation of AF (\( P = 0.010 \)). Diabetes mellitus was less common (\( P = 0.013 \)), coronary artery disease was more common (\( P = 0.049 \)), systolic blood pressure (SBP, \( P = 0.020 \)) and diastolic blood pressure (DBP, \( P = 0.019 \)) were lower, heart rate was slower (\( P = 0.015 \)), serum brain natriuretic peptide (BNP) was higher (\( P < 0.001 \)), and both the atrial premature contraction (APC) count (\( P = 0.002 \)) and short runs of APCs (\( P < 0.001 \)), meaning triplets or more multiple runs, on the 24-h Holter ECG were more common in those with AF than in those without
Table 1. Baseline characteristics of the patients

|                          | Total, n=206 | AF (+), n=14 | AF (−), n=192 | P    |
|--------------------------|--------------|--------------|---------------|------|
| **Demographics**         |              |              |               |      |
| Age, y                   | 71 (61–78.3) | 75.5 (73.3–83.5) | 69.5 (61–78) | 0.010 |
| Female sex               | 75 (36.4)    | 4 (28.6)     | 71 (37.0)     | 0.52 |
| **Comorbidities / medical history** |          |              |               |      |
| Hypertension             | 139 (67.5)   | 11 (78.6)    | 128 (66.7)    | 0.34 |
| Diabetes mellitus        | 39 (18.9)    | 0 (0)        | 39 (20.3)     | 0.013 |
| Dyslipidemia             | 103 (50.0)   | 5 (35.7)     | 98 (51.0)     | 0.27 |
| Heart failure            | 2 (1.0)      | 1 (1.7)      | 1 (0.5)       | 0.09 |
| Chronic kidney disease   | 10 (4.9)     | 1 (7.1)      | 9 (4.7)       | 0.70 |
| Coronary artery disease  | 13 (6.3)     | 3 (21.4)     | 10 (5.2)      | 0.049 |
| Peripheral artery disease| 0 (0)        | 0 (0)        | 0 (0)         | –    |
| Previous ischemic stroke except for the index one | 35 (17.0) | 2 (14.3) | 33 (17.2) | 0.76 |
| CHADS2 score             | 1 (1–2)      | 1.5 (1–2)    | 1 (1–2)       | 0.56 |
| CHA2DS2-VASc score       | 3 (2–4)      | 3 (2–4)      | 3 (1–4)       | 0.28 |
| **Physiological data on admission** |          |              |               |      |
| Body mass index, kg/m²   | 22.9 (20.8–25.4) | 21.7 (19.6–24.8) | 22.9 (20.9–25.4) | 0.23 |
| Systolic blood pressure, mmHg | 160 (139–179) | 147 (130–158.5) | 160.5 (139–180.8) | 0.020 |
| Diastolic blood pressure, mmHg | 87 (76–100)   | 76 (71.5–83.8) | 88 (78–100)   | 0.019 |
| Heart rate, /min         | 78 (67–88.3) | 68.5 (63.3–74.3) | 78 (68–89.8) | 0.015 |
| **Features of stroke**   |              |              |               |      |
| National Institutes of Health Stroke Scale score | 2 (1–5) | 2.5 (0–4) | 2 (1–5) | 0.98 |
| Infarct diameter < 1.5 cm| 73 (36.4%)   | 5 (35.7)     | 68 (35.4)     | 0.98 |
| **Location of infarcts** |              |              |               |      |
| Anterior circulation alone | 128 (62.1) | 10 (71.4) | 118 (61.4) | 0.12 |
| Posterior circulation alone | 50 (24.3) | 4 (28.6) | 46 (24.0) |      |
| Both                     | 28 (13.6)    | 0            | 28 (14.6)     |      |
| **Blood test**           |              |              |               |      |
| Serum creatinine, mg/dL  | 0.76 (0.65–0.89) | 0.78 (0.72–0.93) | 0.75 (0.65–0.89) | 0.31 |
| Brain natriuretic peptide (BNP), pg/mL | 32.1 (13.4–83.0) | 114.8 (40.1–198.8) | 28.4 (12.5–67.1) | <0.001 |
| BNP ≥66 pg/mL¹            | 58 (28.2)    | 10 (71.4)    | 48 (25.0)     | <0.001 |
| D-dimer, µg/mL            | 0.7 (0.5–1.2) | 0.7 (0.7–4.2) | 0.7 (0.5–1.1) | 0.074 |
| **Transesophageal echocardiography** | | | | |
| Left atrial diameter, mm | 35 (31–39) | 37.5 (32.6–42) | 35 (31–39) | 0.13 |
| Left atrial diameter ≥36.0 mm¹ | 82 (39.8) | 10 (71.4) | 74 (38.5) | 0.067 |
| Left ventricular ejection fraction, % | 64.1 (61–70) | 62.3 (54.8–69.8) | 64.3 (61–70) | 0.22 |
| **24-hour Holter electrocardiography** | | | | |
| Atrial premature contractions (APCs), /24 h | 80 (22–383) | 391 (152–946) | 64 (19–312) | 0.002 |
| APCs ≥345 beats /24h¹     | 55 (26.7)    | 9 (64.3)     | 46 (24.0)     | 0.002 |
| APC short runs, /24 h     | 1 (0–3)      | 8.5 (1–22)   | 1 (0–3)       | <0.001 |
| APC short runs ≥13 /24 h¹ | 25 (12.1)    | 7 (50.0)     | 18 (9.4)      | <0.001 |
| **7-day Holter monitoring** | | | | |
| Day after stroke onset, d | 13 (9–19) | 10.5 (7.8–24.3) | 13 (9–18) | 0.69 |

N (%); or median (IQR).

*Scores prior to the index stroke

¹Each cutoff value was determined by receiver operating characteristic curve analysis.

(Table 1).

Baseline characteristics that were independently associated with AF detection were determined by multivariate analysis with the variables showing P<0.05 on univariate analysis (SBP was excluded from the variables due to its strong interaction with DBP, and diabetes was excluded due to no positive patients in the AF group) plus left atrial diameter (LAD) as a representative biomarker of echocardiography. BNP level was positively associated with AF, independent of
other variables (Table 2).

**Cutoff Levels of Pre-Entry Biomarkers for Predicting AF**

The optimal cutoff levels of the biomarkers obtained by blood testing, transthoracic echocardiography, and 24-h Holter ECG prior to 7-day Holter monitoring that were predictive of AF detection were investigated. As the most powerful candidates of each examination, BNP was chosen among blood test findings, LAD was chosen among echocardiography findings, and the total counts of APCs and the short runs of APCs were chosen among the 24-h Holter ECG findings. Fig. 3 shows the distribution of these four components for patients with and without AF detection. Fig. 4 shows the associations of pairs of the four components.

The cutoff level of BNP based on the ROC curve
and 0.71, with the highest level for BNP (Table 3). Specificity varied between 0.53 and 0.90, with the highest level for short runs of APCs. Positive predictive values did not reach 0.3, and negative predictive values were 0.96 or 0.97 for all.

Table 2. Associations of baseline characteristics (continuous variables) with detection of atrial fibrillation

| Characteristic                                         | Odds ratio (95% CI) | P    |
|--------------------------------------------------------|---------------------|------|
| Age, per 10-year                                       | 1.78 (0.91–3.51)    | 0.093|
| Coronary artery disease                                | 2.09 (0.38–11.47)   | 0.394|
| Diastolic blood pressure, per 10-mmHg                 | 0.73 (0.45–1.19)    | 0.209|
| Heart rate, per 10-beat/min                           | 0.61 (0.36–1.03)    | 0.063|
| Brain natriuretic peptide, per 10-pg/mL               | 1.09 (1.03–1.17)    | 0.007|
| Left atrial diameter, per 1-mm                         | 1.07 (0.99–1.17)    | 0.084|
| Atrial premature contraction (APC), per 100-beats/24 h | 0.99 (0.97–1.01)    | 0.502|
| APC short runs, per 1/24 h                             | 1.00 (1.00–1.00)    | 0.999|

*Adjusted by age, diastolic blood pressure, heart rate, brain natriuretic peptide and left atrial diameter
CI: confidence interval

Fig. 3. Distribution of data from the pre-entry screening examinations

Horizontal lines show cutoff levels for predicting detection of atrial fibrillation by ROC curve analysis. Box and whisker plots show 10th, 25th, 50th, 75th, and 90th percentile values.
AF: atrial fibrillation

Analysis was 66.0 pg/mL with area under the curve (AUC) of 0.77, that of LAD was 36.0 mm with AUC of 0.62, that of APCs was 345 beats/24h with AUC of 0.75, and that of short runs of APCs was 13 beats/24h with AUC of 0.75. Sensitivity varied between 0.50 and 0.71, with the highest level for BNP (Table 3). Specificity varied between 0.53 and 0.90, with the highest level for short runs of APCs. Positive predictive values did not reach 0.3, and negative predictive values were 0.96 or 0.97 for all.
A total of 83 patients (median age 74 years, 36 women) were enrolled in the validation cohort between October 2016 and April 2020. Table 4 summarizes the baseline clinical characteristics of the cohort. The device identified AF in 24 patients (29%, 95% CI 20.3%–39.4%), the detection rate being 37% (11/30) in patients initiating monitoring within 30 days after onset of stroke, 35% (6/17) in those within

Exceeding each of these four cutoff levels was associated with AF detection independent of age, coronary artery disease, DBP, and HR, with adjusted odds ratios between 3.19 (for LAD) and 7.17 (for short runs of APCs, Table 3). Simultaneously exceeding any two of these four cutoff levels was also independently associated with AF detection, with the adjusted odds ratios between 7.17 and 19.56.

Validation

A total of 83 patients (median age 74 years, 36 women) were enrolled in the validation cohort between October 2016 and April 2020. Table 4 summarizes the baseline clinical characteristics of the cohort. The device identified AF in 24 patients (29%, 95% CI 20.3%–39.4%), the detection rate being 37% (11/30) in patients initiating monitoring within 30 days after onset of stroke, 35% (6/17) in those within
Discussion

First, the ambulatory 7-day Holter monitoring detected previously unidentified AF in 6.8% (95% CI: 4.1%–11.1%) of the patients with recently diagnosed ESUS after completion of the standard clinical workup including 24-h Holter ECG. Second, the median time delay from starting the 7-day Holter monitoring to the first AF documentation was 50 h. Third, the serum BNP level and the APC count and short runs of APCs on 24-h Holter ECG in the standard workup seemed to be predictors of covert AF.

The rate of newly detected AF after ischemic stroke varies widely depending on its definition (minimal duration, etc.), study population, duration of cardiac monitoring, monitoring devices (e.g., Holter ECG, external loop recorders, or implantable loop recorders), and interval from stroke onset to the start of monitoring. Meta-analyses revealed that the detection rate of AF in patients with ischemic stroke using ambulatory Holter monitoring for 1 to 7 days was 10.7% (95% CI: 5.6%–17.2%) and that using monitoring for ≥ 7 days was 15% (11%–19%). The present rate of AF detection was low compared to previous reports. A possible reason was that continuous cardiac monitoring during patients’ stay in stroke care units for several days was often performed in addition to the 24-h Holter ECG as the standard clinical workup in the participating institutes. Moreover, this process might decrease the chance to register patients with covert AF, which could relatively easily appear into the 7-day Holter monitoring. Additionally, the detection rate of AF reportedly declines with the lapse of time after onset of stroke as was also shown in the present validation cohort. In the derivation cohort, the first three quartile groups by the delay of initiation of the 7-day Holter showed the similar tendency, but the last quartile group did not, which was presumably partly due to the statistical error with the small patient number of each quartile group.

The rate of AF detection using insertable monitors was generally higher than that by the 7-day monitoring, being 8.9% at 6 months and 30.0% at 36 months in patients with cryptogenic stroke in the Cryptogenic Stroke and Underlying AF (CRYSTAL AF) trial. A high rate of 26% for a median follow-up of 7 months was reported in a multicenter registry in Japan, including one of the present participating institutes, in which the aforementioned diagnostic criteria for ESUS in accordance with current medical practice in Japan were used. Despite its weaker detection power, the 7-day Holter monitoring seemed to have some features, making it superior to insertable monitors, such as noninvasiveness and low cost. Additionally, the present device can identify a transient AF episode lasting seconds, although regular insertable monitors have some features, making it superior to insertable monitors.
duration of algorithms for automated detection of AF rather than on scientific grounds.

All of serum BNP, LAD, and APC counts are promising predictors for covert AF that later appeared in long-term monitoring with reported optimal cutoff levels of $>70–100$ pg/mL, $>45$ mm, and $>222$ beats/24 h, respectively $^{24,27}$. Of several blood biomarkers, elevated BNP, high levels of N-terminal pro-hormone of BNP, midregional pro-atrial natriuretic peptide, fibroblast growth factor-23, and Galectin three were reportedly associated with AF.$^{28,32}$. Compared to these blood biomarkers, d-dimer and other known coagulation markers might be less predictive of AF detection.$^{29}$. BNP and LAD, along with P-wave terminal force in lead V1 on ECG, seem to also be associated with atrial cardiopathy, a potential embolicogenic pathology to the brain.$^{4,33}$. Of these, P-wave terminal force in lead V1 seemed to have a problem of interobserver variability; thus, we accordingly planned to analyze the marker with central reading in a future study separate from the other handy markers. The significance of short runs of APCs has remained unclear. Any episode of runs of $\geq20$ APCs in the 48-h Holter monitoring was reported to be predictive of AF development in the healthy cohort.$^{34}$, and $>5$-beat/24-h APC runs in the 7-day Holter monitoring were reported to be predictive of AF in the stroke patients.$^{35}$. LAD did not show a significant difference between patients with and without AF detection in the present univariate analysis, and its cutoff value of 36.0 mm had relatively low specificity (0.53) compared to the others (0.75–0.90). Since the present cutoff of LAD was smaller compared with the reported value, and old Japanese patients often have a small stature, correction of LAD by body surface area would be better. BNP and APCs might accordingly be more promising biomarkers for choosing candidates with ESUS requiring somewhat invasive long-term cardiac monitoring. The superiority of BNP and APCs as predictors of AF to LAD was shown in the present validation cohort.

The limitations of the present study included the small number of patients with AF detection, limiting statistical power for some comparisons. In addition, the validation analysis was performed using different diagnostic tools (insertable cardiac monitors) from 7-day Holter monitoring; these two tools have different power to detect covert AF.

## Conclusion

With ambulatory 7-day Holter monitoring, AF was newly detected in $\approx7\%$ of patients recently diagnosed with ESUS. Several serological, imaging, and electrocardiographic markers obtained at pre-entry screening seem promising as predictors of covert AF.

## Acknowledgments

We thank Drs Masafumi Ihara, Masatoshi Koga, Yoshitaka Yamaguchi, Naoki Makita, and Hajime Ike-nouchi from National Cerebral and Cardiovascular Center and Dr. Kana Ueki from NHO Kyushu Medical Center for their contribution to data acquisition.

## Disclosures

No authors disclose conflict of interest related to the manuscript.

This study was supported by Grants from the Japan Agency for Medical Research and Development (AMED: 20lk0201094h0002, 20lk0201109h0001) and a grant from SENSHIN Medical Research Foundation.

## References

1) Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, Sacco RL, Connolly SJ: Crypto genic Stroke/ESUS International Working Group: Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol, 2014; 13(4): 429-438
2) Toyoda K, Okumura K, Hashimoto Y, Ikeda T, Komatsu T, Hirano T, Fukuda H, Matsumoto K, Yasaka M: Identification of covert atrial fibrillation in cryptogenic ischemic stroke: current clinical practice in Japan. J Stroke Cerebrovasc Dis, 2016; 25(8): 1829-1837
3) Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ: Embolic stroke of undetermined source: a systematic review and clinical update. Stroke, 2017; 48(4): 867-872
4) Kamel H, Okin PM, Elkind MS, Iadecola C: Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke, 2016; 47(3): 895-900
5) Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007; 146(12): 857-867
6) Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P: Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke, 2017; 12(6): 589-596
7) Diener HC, Bernstein R, Hart R: Secondary stroke prevention in cryptogenic stroke and embolic stroke of undetermined source (ESUS). Curr Neurol Neurosci Rep, 2017; 17(9): 64
8) Hart RG, Sharma M, Mundh L, Kasner SE, Bangdiwa SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauza A, Lang W, Czlonkowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T,
9) Diener H-C, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, Kreuzer T, Cronin L, Cotton D, Grauer C, Bruckmann M, Chernyatina M, Donnan G, Ferro JM, Grond M, Kallmünzer B, Krupinski J, Lee BC, Lemmens R, Masjuan J, Oedin M, Saver JL, Schellinger PD, Toni D, Toyoda K; RE-SPECT ESUS Steering Committee and Investigators: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med, 2019; 380(20): 1906-1917

10) European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis, 2008; 25(5): 457-507

11) Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL: Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2019; 50(12): e344-e418

12) Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O'Donnell M, Laupacis A, Côté R, Sharma M, Blakely JA, Shuaib A, Hachinski V, Coutts SB, Sahlas DJ, Teal P, Yip S, Spence JD, Buck B, Verreault S, Casaubon LK, Penn A, Selchen D, Jin A, Howe D, Mehdiratta M, Boyle K, Avis R, Kapral MK, Mamdani M; EMBRACE Investigators and Coordinators: Atrial fibrillation in patients with cryptogetic stroke. N Engl J Med, 2014; 370(23): 2191-2201

13) Sanna T, Diener H-C, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, Lindborg K, Brachmann J; CRYSTAL AF Investigators: Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med, 2014; 370(26): 2478-2486

14) Wachter R, Gröschel K, Gelbrich G, Hamann GF, Kerner P, Liman J, Seegers J, Wasser K, Schulte A, Jürries F, Messerschmidt A, Behnke N, Gröschel S, Uphaus T, Grings A, Ibis T, Klimpe S, Wagner-Heck M, Arnold M, Protsenko E, Heuschmann PU, Conen D, Weber-Krüger M; Find-AF(randomised) Investigators and Coordinators: Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFRANDOMISED): an open-label randomised controlled trial. Lancet Neurol, 2017; 16(4): 282-290

15) Mairesse GH, Moran P, Van Gelder IC, Elsner C, Rosenqvist M, Mant J, Banerjee A, Gorenek B, Brachmann J, Varma N, Glotz de Lima G, Kalman J, Claes N, Lobban T, Lane D, Lip GYH, Boriani G; ESC Scientific Document Group: Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE). Europace, 2017; 19(10): 1589-1623

16) European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J, 2010; 31(19): 2369-2429

17) Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, Smith CJ: Detection of atrial fibrillation after ischaemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke, 2014; 45(2): 520-526

18) Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V: Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol, 2015; 14(4): 377-387

19) Dussault C, Toeg H, Nathan M, Wang ZJ, Roux J-F, Secemsky E: Electrocardiographic monitoring for detecting atrial fibrillation after ischemic stroke or transient ischemic attack: systematic review and meta-analysis. Circ Arrhythm Electrophysiol, 2015; 8(2): 263-269

20) Wachter R, Gröschel K, Gelbrich G, Hamann GF, Kerner P, Liman J, Seegers J, Wasser K, Schulte A, Jürries F, Messerschmidt A, Behnke N, Gröschel S, Uphaus T, Grings A, Ibis T, Klimpe S, Wagner-Heck M, Arnold M, Protsenko E, Heuschmann PU, Conen D, Weber-Kröger M; Find-AF(randomised) Investigators and Coordinators: Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFRANDOMISED): an open-label randomised controlled trial. Lancet Neurol, 2017; 16(4): 282-290

21) Iwata T, Todo K, Yamagami H, Morimoto M, Hashimoto T, Doijiri R, Furuya H: High detection rate of atrial fibrillation after stroke and transient ischaemic attack in patients with cryptogenic stroke diagnosed by Magnetic Resonance Imaging. J Stroke Cerebrovasc Dis, 2019; 28(9): 2569-2573

22) Giancaterino S, Cipriano LE, Riccio PM, Hachinski V, Saposnik G: Very short paroxysms account for more than half of the cases of atrial fibrillation detected after stroke. Clin Electrophysiol, 2018; 4(11): 1383-1396

23) Sposato LA, Cipriano LE, Riccio PM, Hachinski V, Saposnik G: Few short paroxysms account for more than half of the cases of atrial fibrillation detected after stroke and TIA: a systematic review and meta-analysis. Int J Stroke, 2015; 10(6): 801-807

24) Wallmann D, Tüller D, Wustmann K, Meier P, Isenegger E: Electrocardiographic monitoring for detecting atrial fibrillation in patients with cryptogenic stroke: an opportunity for a new diagnostic strategy. Stroke, 2008; 39(8): 2292-2294

25) Poli S, Diedler J, Härtig F, Götz N, Bauer A, Sachse T, Müller K, Müller I, Stimpfle F, Duckheim M, Steeg M, Eick C, Schreieck J, Gawaz M, Ziemann U, Zuern CS: Insertable cardiac monitors after cryptogenic stroke--a risk factor based approach to enhance the detection rate for paroxysmal atrial fibrillation. Eur J Neurol, 2016; 23(2): 553
375-381

26) Wasser K, Weber-Krüger M, Gröschel S, Uphaus T, Liman J, Hamann GF, Kermer P, Seegers J, Binder L, Gelbrich G, Gröschel K, Wächter R: Brain natriuretic peptide and discovery of atrial fibrillation after stroke: a subanalysis of the Find-AF(RANDOMISED) Trial. Stroke, 2020; 51(2): 395-401

27) Todo K, Iwata T, Doijiri R, Yamagami H, Morimoto M, Hashimoto T, Sonoda K, Yamazaki H, Junpei K, Okazaki S, Sasaki T, Mochizuki H: Frequent premature atrial contractions in cryptogenic stroke predict atrial fibrillation detection with insertable cardiac monitoring. Cerebrovasc Dis, 2020; 49(2): 144-150

28) Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB, Tofler GH, Selhub J, Jacques PF, Wolf PA, Magnani JW, Ellinor PT, Wang TJ, Levy D, Vasan RS, Benjamin EJ: Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation, 2010; 121(2): 200-207

29) Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A, Platonov PG, Hedblad B, Engström G, Wang TJ, Melander O: Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol, 2010; 56(21): 1712-1719

30) Sinner MF, Stepas KA, Moser CB, Krijthe BP, Aspelund T, Sotoodehnia N, Fontes JD, Janssens AC, Kronmal RA, Magnani JW, Wittman JC, Chamberlain AM, Lubitz SA, Schnabel RB, Vasan RS, Wang TJ, Agarwal SK, McManus DD, Franco OH, Yin X, Larson MG, Burke GL, Launer LJ, Hofman A, Levy D, Gottdiener JS, Kääb S, Couper D, Harris TB, Astor BC, Ballantyne CM, Hoogeveen RC, Arai AE, Soliman EZ, Ellinor PT, Stricker BH, Gudnason V, Heckbert SR, Pencina MJ, Benjamin EJ, Alonso A: B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace, 2014; 16(10): 1426-1433

31) Ho JE, Yin X, Levy D, Vasan RS, Magnani JW, Ellinor PT, McManus DD, Lubitz SA, Larson MG, Benjamin EJ: Galectin 3 and incident atrial fibrillation in the community. Am Heart J, 2014; 167(5): 729-734

32) Chua W, Purmah Y, Cardoso VR, Gkoutos GV, Tull SP, Neculau G, Thomas MR, Kotecha D, Lip GYH, Kirchhof P, Fabritz L: Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. Eur Heart J, 2019; 40(16): 1268-1276

33) Kamel H, Longstreth WT Jr, Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY, Meinerz C, Dillon C, Ewing I, Spilker JA, Di Tullio MR, Hod EA, Soliman EZ, Chaturvedi S, Moy CS, Janis S, Elkind MS: The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. Int J Stroke, 2019; 14(2): 207-214

34) Binici Z, Intzilakis T, Nielsen OW, Køber L, Sajadieh A: Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation, 2010; 121(17): 1904-1911

35) Weber-Krüger M, Lutz C, Zapf A, Stahrenberg R, Seegers J, Wiitzhenhausen J, Wasser K, Hasenfuß G, Gröschel K, Wächter R: Relevance of supraventricular runs detected after cerebral ischemia. Neurology, 2017; 89(15): 1545-1552